CLASS II Device recall · Reported 13 Apr 2016 · FDA Enforcement Report

Cellex Photopheresis System is a photoimmune therapy recalled

Therakos is recalling Cellex Photopheresis System is a photoimmune therapy, distributed nationwide in the US. The recall was initiated on 21 Dec 2015 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesMfr lot #D342
Quantity recalled729 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1322-2016
FDA event ID
73012
Recalling firm
Therakos, West Chester, PA
Classification
Class II
Status
Terminated
Recall initiated
21 Dec 2015
FDA classified
5 Apr 2016
Reported
13 Apr 2016
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects

Timeline

21 Dec 2015Recall initiated by company
5 Apr 2016Classified by FDA+106 days
13 Apr 2016Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The Mallinckrodt (Therakos) post-market monitoring process detected an increased trend in tubing leaks within the pump tubing organizer, associated with a portion of Kits from Lot D 342.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

The THERAKOS CELLEX Photopheresis System is a photoimmune therapy. Catalog CLXUSA. Manufacturing lot D342 UDI: 20705030200003 The system designed to separate the patient's blood into various fractions and collect the white blood cell (WBC) fraction. The WBC fraction is treated with a photoactive drug UVADEX¿ (methoxsalen) Sterile Solution. The UVADEX is photo-activated by UVA light and results in the WBCs undergoing apoptosis

Where it was distributed

Nationwide Distribution to AL, AZ, CA, CO, DC, FL, ID, IL, IN, MA, ME, MN, MO, NC, NJ, NY, OH, PA, SC, TN, TX, UT, VT, AND WI.

Nationwide AlabamaArizonaCaliforniaColoradoDistrict of ColumbiaFloridaIdahoIllinoisIndianaMassachusettsMaineMinnesotaMissouriNorth CarolinaNew JerseyNew YorkOhioPennsylvaniaSouth CarolinaTennessee

Questions about this recall

Why was it recalled?

The Mallinckrodt (Therakos) post-market monitoring process detected an increased trend in tubing leaks within the pump tubing organizer, associated with a portion of Kits from Lot D 342.

Which lots are affected?

Mfr lot #D342

Where was it sold?

Nationwide Distribution to AL, AZ, CA, CO, DC, FL, ID, IL, IN, MA, ME, MN, MO, NC, NJ, NY, OH, PA, SC, TN, TX, UT, VT, AND WI.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Therakos

All 2
ReportedClassRecallCompanyReasonWhere
DeviceCLASS IICellex Photopheresis Procedural Kit Product recalled by TherakosTherakosPackaging DefectsIL

Other Other Medical Devices recalls

All 13,778